Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6UVM3
UPID:
KCNT2_HUMAN
Alternative names:
Sequence like an intermediate conductance potassium channel subunit; Sodium and chloride-activated ATP-sensitive potassium channel Slo2.1
Alternative UPACC:
Q6UVM3; Q3SY59; Q5VTN1; Q6ZMT3
Background:
Potassium channel subfamily T member 2, also known as Slo2.1, is an outward rectifying potassium channel. It is activated by high intracellular sodium and chloride levels and plays a crucial role in maintaining the cell's electrical stability. Slo2.1 is inhibited by ATP and certain inhalation anesthetics like isoflurane, and its activity decreases upon stimulation of G-protein coupled receptors such as CHRM1 and GRM1.
Therapeutic significance:
Slo2.1 is implicated in Developmental and Epileptic Encephalopathy 57 (DEE57), a severe early-onset epilepsy with neurodevelopmental impairment. Given its role in this condition, targeting Slo2.1 could offer new avenues for therapeutic intervention in DEE57 and potentially other related neurological disorders.